Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Gabapentin reverses endocannabinoid - independent colitis

Gabapentin reverses endocannabinoid - independent colitis

A. Batista, Jalles
A. Magalhães, Diva
L. R. Barbosa, André

Paperback

Medical Reference

ISBN10: 6207646568
ISBN13: 9786207646562
Publisher: Our Knowledge Publishing
Published: May 13 2025
Pages: 64
Weight: 0.22
Height: 0.15 Width: 6.00 Depth: 9.00
Language: English
Inflammatory bowel disease (IBD) comprises a spectrum of diseases characterized by chronic inflammation of the gastrointestinal tract without a specific cause or pathogen. Gabapentin (GBP) is an anticonvulsant drug, but previous studies show that it is effective in reducing gastric inflammatory damage and decreasing the acute inflammatory process. During colitis, there is an increase in substances that act on the endocannabinoid pathway, which are important for protecting the colon during the development of the inflammatory intestinal process. Therefore, the aim of this study was to analyze the anti-inflammatory effect of GBP on acetic acid (AA)-induced colitis in mice and to see whether this mechanism of action is due to the pharmacological endocannabinoid pathway. The results show that AA was effective in inducing ulcerative colitis (UC); that GBP reduces inflammation in the colon caused by AA, however, its effect is probably independent of the endocannabinoid receptor pathway, which is not involved in reducing the inflammatory effect of experimentally induced UC, showing that this pathway does not represent a promising therapeutic alternative for patients with UC.

Also from

A. Batista, Jalles

View All

Also in

Medical Reference

View All